Goldman Sachs’s Phathom Pharmaceuticals PHAT Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.85M | Buy |
192,526
+4,652
| +2% | +$44.6K | ﹤0.01% | 3468 |
|
|
2025
Q1 | $1.18M | Sell |
187,874
-224,388
| -54% | -$1.41M | ﹤0.01% | 3694 |
|
|
2024
Q4 | $3.35M | Sell |
412,262
-21,959
| -5% | -$178K | ﹤0.01% | 3147 |
|
|
2024
Q3 | $7.85M | Buy |
434,221
+16,937
| +4% | +$306K | ﹤0.01% | 2438 |
|
|
2024
Q2 | $4.3M | Buy |
417,284
+209,912
| +101% | +$2.16M | ﹤0.01% | 2719 |
|
|
2024
Q1 | $2.2M | Sell |
207,372
-2,839
| -1% | -$30.2K | ﹤0.01% | 3150 |
|
|
2023
Q4 | $1.92M | Buy |
210,211
+71,711
| +52% | +$655K | ﹤0.01% | 3233 |
|
|
2023
Q3 | $1.44M | Sell |
138,500
-16,168
| -10% | -$168K | ﹤0.01% | 3300 |
|
|
2023
Q2 | $2.21M | Buy |
154,668
+105,987
| +218% | +$1.52M | ﹤0.01% | 3143 |
|
|
2023
Q1 | $348K | Sell |
48,681
-25,331
| -34% | -$181K | ﹤0.01% | 4265 |
|
|
2022
Q4 | $830K | Buy |
74,012
+16,670
| +29% | +$187K | ﹤0.01% | 3803 |
|
|
2022
Q3 | $635K | Buy |
57,342
+4,970
| +9% | +$55K | ﹤0.01% | 4098 |
|
|
2022
Q2 | $442K | Buy |
52,372
+24,035
| +85% | +$203K | ﹤0.01% | 4460 |
|
|
2022
Q1 | $386K | Sell |
28,337
-5,780
| -17% | -$78.7K | ﹤0.01% | 4743 |
|
|
2021
Q4 | $671K | Buy |
34,117
+26,954
| +376% | +$530K | ﹤0.01% | 4317 |
|
|
2021
Q3 | $230K | Buy |
+7,163
| New | +$230K | ﹤0.01% | 4805 |
|
|
2021
Q1 | – | Sell |
-44,078
| Closed | -$1.46M | – | 5331 |
|
|
2020
Q4 | $1.46M | Buy |
+44,078
| New | +$1.46M | ﹤0.01% | 3246 |
|
|
2020
Q1 | – | Sell |
-6,492
| Closed | -$202K | – | 4523 |
|
|
2019
Q4 | $202K | Buy |
+6,492
| New | +$202K | ﹤0.01% | 3985 |
|